Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Objective: To investigate the current clinical practice of sentinel lymph node biopsy (SLNB) in patients with early stage breast cancer in China. Methods: The data of early breast cancer patients who underwent SLNB in 40 Grade III Level A hospitals in China in 2018 will be collected. Different centers, tracer methods, molecular typing and neoadjuvant chemotherapy will be used as stratification factors to analyze the implementation rate, number of detections, positive rate of SLNB and the follow-up treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| performed SLNB using a single mapping agent |
| ||
| performed SLNB by combination of blue dye and radiotracer |
| ||
| underwent SLN surgery receiving neoadjuvant chemotherapy |
| ||
| underwent SLN surgery not receiving neoadjuvant chemotherapy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| mapping agent | Diagnostic Test | according to different tracer methods, patients are divided into the implementation of a single mapping agent and implementation of combination of blue dye and radiotracer agent. |
| Measure | Description | Time Frame |
|---|---|---|
| the performance rate of sentinel lymph node biopsy (SLNB) in patients with early stage breast cancer in China | the performance rate of SLNB refers to the number of patients implementing SLNB divided by the total number of breast cancer patients | 2020-12-31 |
| the positive rate of SLNs in patients with early stage breast cancer in China | SLNs positive rate is the number of positive SLN patients divided by the number of patients implementing SLNB | 2020-12-31 |
| the number of resected SLNs in patients with early stage breast cancer in China | the average number of resected SLNB will be calculated | 2020-12-31 |
| Measure | Description | Time Frame |
|---|---|---|
| incidence of infection events after SLNB in patients with early stage breast cancer in China | incidence of infection events is the number of patients who have an infection event after SLNB divided by the total number of patients implementing SLNB. The infection events include incision infection, local skin infection and injured vascular infection. | 2021-12-31 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
early breast cancer patients who underwent SLNB in 40 Grade III Level A hospitals in China in 2018
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Juliang Zhang | Contact | 029-84775271 | 13572900544 | ycj617655094@163.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Xijing hospital | Recruiting | Xi'an | Shaanxi | 710032 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D020360 | Neoadjuvant Therapy |
| ID | Term |
|---|---|
| D003131 | Combined Modality Therapy |
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
| neoadjuvant chemotherapy | Procedure | Patients were divided into two groups based on whether they were receiving neoadjuvant chemotherapy. |
|
| D017437 |
| Skin and Connective Tissue Diseases |